End-of-day quote
Toronto S.E.
06:00:00 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
11.57
CAD
|
+0.17%
|
|
+4.33%
|
+12.55%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
48.87
|
18.34
|
26.57
|
43.69
|
15.4
|
9.413
|
Enterprise Value (EV)
1 |
35.1
|
11.41
|
2.486
|
-21.45
|
-35.03
|
-24.32
|
P/E ratio
|
12.4
x
|
-2.62
x
|
-3.4
x
|
-4.94
x
|
-0.68
x
|
-0.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.82
x
|
34.5
x
|
7.28
x
|
8.31
x
|
2.73
x
|
2.09
x
|
EV / Revenue
|
1.31
x
|
21.4
x
|
0.68
x
|
-4.08
x
|
-6.21
x
|
-5.41
x
|
EV / EBITDA
|
3.55
x
|
-1.18
x
|
-0.42
x
|
2.48
x
|
2.28
x
|
1.35
x
|
EV / FCF
|
6.14
x
|
-2.09
x
|
-0.74
x
|
4.51
x
|
3.89
x
|
2.38
x
|
FCF Yield
|
16.3%
|
-47.9%
|
-135%
|
22.2%
|
25.7%
|
42%
|
Price to Book
|
25.6
x
|
-7.43
x
|
2.01
x
|
0.82
x
|
0.43
x
|
0.52
x
|
Nbr of stocks (in thousands)
|
164
|
200
|
627
|
1,214
|
1,214
|
1,214
|
Reference price
2 |
297.3
|
91.55
|
42.40
|
35.99
|
12.68
|
7.754
|
Announcement Date
|
3/29/19
|
3/30/20
|
3/24/21
|
3/28/22
|
3/23/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
26.88
|
0.532
|
3.652
|
5.26
|
5.64
|
4.498
|
EBITDA
1 |
9.9
|
-9.676
|
-5.896
|
-8.646
|
-15.36
|
-17.99
|
EBIT
1 |
9.842
|
-9.713
|
-5.925
|
-8.671
|
-15.38
|
-18.01
|
Operating Margin
|
36.61%
|
-1,825.75%
|
-162.24%
|
-164.85%
|
-272.64%
|
-400.36%
|
Earnings before Tax (EBT)
1 |
9.639
|
-6.23
|
-4.723
|
-8.477
|
-22.73
|
-16.55
|
Net income
1 |
4.187
|
-6.042
|
-5.118
|
-8.368
|
-22.73
|
-16.55
|
Net margin
|
15.58%
|
-1,135.71%
|
-140.14%
|
-159.09%
|
-402.96%
|
-367.99%
|
EPS
2 |
24.00
|
-35.00
|
-12.46
|
-7.281
|
-18.72
|
-13.63
|
Free Cash Flow
1 |
5.716
|
-5.464
|
-3.361
|
-4.755
|
-9.008
|
-10.21
|
FCF margin
|
21.27%
|
-1,027.04%
|
-92.03%
|
-90.39%
|
-159.72%
|
-226.99%
|
FCF Conversion (EBITDA)
|
57.74%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
136.52%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/19
|
3/30/20
|
3/24/21
|
3/28/22
|
3/23/23
|
3/27/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
3.473
|
1.517
|
-0.222
|
1.86
|
2.485
|
2.128
|
2.246
|
0.003
|
0.121
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.423
|
-2.813
|
-4.716
|
-3.721
|
-12.35
|
-4.207
|
-2.855
|
-4.55
|
-6.396
|
Operating Margin
|
-98.56%
|
-185.43%
|
2,124.32%
|
-200.05%
|
-497.1%
|
-197.7%
|
-127.11%
|
-151,666.67%
|
-5,285.95%
|
Earnings before Tax (EBT)
1 |
-3.166
|
-2.64
|
-4.216
|
-3.42
|
-12.45
|
-4.255
|
-2.518
|
-4.145
|
-5.635
|
Net income
1 |
-3.186
|
-2.64
|
-4.2
|
-3.42
|
-12.45
|
-4.255
|
-2.518
|
-4.145
|
-5.635
|
Net margin
|
-91.74%
|
-174.03%
|
1,891.89%
|
-183.87%
|
-501.05%
|
-199.95%
|
-112.11%
|
-138,166.67%
|
-4,657.02%
|
EPS
2 |
-2.000
|
-2.000
|
-3.480
|
-2.800
|
-10.24
|
-3.520
|
-2.080
|
-3.400
|
-4.640
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/10/22
|
8/3/22
|
11/3/22
|
3/23/23
|
5/9/23
|
8/9/23
|
11/9/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
13.8
|
6.93
|
24.1
|
65.1
|
50.4
|
33.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
5.72
|
-5.46
|
-3.36
|
-4.75
|
-9.01
|
-10.2
|
ROE (net income / shareholders' equity)
|
-956%
|
2,173%
|
-95.2%
|
-25.3%
|
-51.2%
|
-61.3%
|
ROA (Net income/ Total Assets)
|
26.1%
|
-27%
|
-12.9%
|
-9.26%
|
-14.1%
|
-24.2%
|
Assets
1 |
16.07
|
22.39
|
39.57
|
90.41
|
161
|
68.42
|
Book Value Per Share
2 |
11.60
|
-12.30
|
21.10
|
43.60
|
29.50
|
15.00
|
Cash Flow per Share
2 |
88.30
|
39.20
|
38.70
|
53.80
|
41.70
|
28.00
|
Capex
1 |
0.01
|
-
|
-
|
0.03
|
0.01
|
0.02
|
Capex / Sales
|
0.03%
|
-
|
-
|
0.57%
|
0.2%
|
0.42%
|
Announcement Date
|
3/29/19
|
3/30/20
|
3/24/21
|
3/28/22
|
3/23/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| +12.55% | 10.32M | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B | | -6.26% | 11.42B |
Other Biotechnology & Medical Research
|